Healthcare provider profile · identity verified

Robert C Bransfield, M. D.

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · RED BANK, NJ · NPI 1467449769

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Robert C Bransfield, M. D. received $112,559.09 in general payments during 2025 across 215 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 98.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 19 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Azstarys, Caplyta, Dyanavel Xr, Rexulti, Sunosi, Vraylar, Xywav.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VIIBRYD as an associated drug or biological on 57 records involving 55 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Viibryd by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Vraylar by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Sunosi by this doctor in 2024.

Corium, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Azstarys as an associated drug or biological on 54930 records involving 15827 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Azstarys by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Caplyta by this doctor in 2024.

JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Xywav by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rexulti by this doctor in 2024.

Tris Pharma Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Dyanavel XR as an associated drug or biological on 17868 records involving 7985 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Dyanavel Xr by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$112,559.09

215 reported records · 15 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$110,752.52	98.4%	115	2025
JAZZ PHARMACEUTICALS INC.	Unresolved — no canonical attribution shown	$345.58	0.3%	13	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$272.50	0.2%	12	2025
Bausch Health US, LLC	Unresolved — no canonical attribution shown	$225.90	0.2%	17	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$185.77	0.2%	11	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$173.12	0.1%	12	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$169.50	0.1%	5	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$145.30	0.1%	11	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$96.21	0.1%	6	2025
Almatica Pharma LLC	Unresolved — no canonical attribution shown	$78.12	0.1%	5	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$51.02	0.1%	3	2025
Tris Pharma Inc	Unresolved — no canonical attribution shown	$27.60	0.0%	2	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$15.22	0.0%	1	2025
HARMONY BIOSCIENCES LLC	Unresolved — no canonical attribution shown	$14.11	0.0%	1	2025
Corium, LLC	Unresolved — no canonical attribution shown	$6.62	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$89,685.00	27
Travel and Lodging	$12,740.51	25
Food and Beverage	$5,482.58	160
Consulting Fee	$4,590.00	2
Education	$61.00	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$110,752.52	115	2025
Source payment records 2025-01-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.17 · Open Payments source 2025-01-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.03 · Open Payments source 2025-01-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-01-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,700.00 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $123.80 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,700.00 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $564.47 · Open Payments source 2025-02-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.01 · Open Payments source 2025-02-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,700.00 · Open Payments source 2025-02-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $41.50 · Open Payments source 2025-02-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.07 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.63 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,700.00 · Open Payments source 2025-02-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $698.45 · Open Payments source 2025-03-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $110.76 · Open Payments source 2025-03-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,320.00 · Open Payments source 2025-03-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $729.76 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.01 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,700.00 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $91.55 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.19 · Open Payments source 2025-04-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $121.03 · Open Payments source 2025-04-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,320.00 · Open Payments source 2025-04-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $690.70 · Open Payments source 2025-04-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $102.40 · Open Payments source 2025-04-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,700.00 · Open Payments source 2025-04-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $581.02 · Open Payments source 2025-04-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,620.00 · Open Payments source 2025-04-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.62 · Open Payments source 2025-04-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,620.00 · Open Payments source 2025-05-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.69 · Open Payments source 2025-05-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.10 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $537.71 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $123.27 · Open Payments source 2025-05-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-05-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.53 · Open Payments source 2025-06-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-06-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.21 · Open Payments source 2025-06-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $120.29 · Open Payments source 2025-06-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $470.86 · Open Payments source 2025-06-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.06 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $106.32 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $487.96 · Open Payments source 2025-06-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $634.69 · Open Payments source 2025-06-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $109.99 · Open Payments source 2025-06-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.72 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-07-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-07-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-07-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.14 · Open Payments source 2025-07-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $120.29 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $979.03 · Open Payments source 2025-07-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.69 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-07-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-08-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.95 · Open Payments source 2025-08-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.65 · Open Payments source 2025-08-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $586.26 · Open Payments source 2025-08-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.05 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.44 · Open Payments source 2025-08-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.37 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-09-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-09-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.66 · Open Payments source 2025-09-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,121.12 · Open Payments source 2025-09-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.59 · Open Payments source 2025-09-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $5,550.00 · Open Payments source 2025-09-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.48 · Open Payments source 2025-09-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.31 · Open Payments source 2025-09-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $656.65 · Open Payments source 2025-09-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $112.98 · Open Payments source 2025-10-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $230.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $267.96 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $44.30 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.08 · Open Payments source 2025-10-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $118.75 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.61 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.94 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.94 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $516.46 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $116.34 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $100.80 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.20 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $85.03 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,079.04 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $120.47 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.71 · Open Payments source 2025-11-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.55 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.58 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-03 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $126.57 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.47 · Open Payments source 2025-12-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $13.92 · Open Payments source 2025-12-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $118.22 · Open Payments source 2025-12-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,323.57 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-12-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.62 · Open Payments source 2025-12-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.07 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $16.52 · Open Payments source
XYWAV Normalized: xywav	Drug	JAZZ PHARMACEUTICALS INC.	$345.58	13	2025
Source payment records 2025-01-23 · JAZZ PHARMACEUTICALS INC. · $13.09 · Open Payments source 2025-01-28 · JAZZ PHARMACEUTICALS INC. · $150.00 · Open Payments source 2025-03-03 · JAZZ PHARMACEUTICALS INC. · $13.97 · Open Payments source 2025-03-19 · JAZZ PHARMACEUTICALS INC. · $10.03 · Open Payments source 2025-04-24 · JAZZ PHARMACEUTICALS INC. · $11.55 · Open Payments source 2025-04-25 · JAZZ PHARMACEUTICALS INC. · $61.00 · Open Payments source 2025-05-22 · JAZZ PHARMACEUTICALS INC. · $13.60 · Open Payments source 2025-06-17 · JAZZ PHARMACEUTICALS INC. · $10.37 · Open Payments source 2025-07-16 · JAZZ PHARMACEUTICALS INC. · $8.22 · Open Payments source 2025-08-20 · JAZZ PHARMACEUTICALS INC. · $10.95 · Open Payments source 2025-10-01 · JAZZ PHARMACEUTICALS INC. · $8.24 · Open Payments source 2025-11-04 · JAZZ PHARMACEUTICALS INC. · $18.28 · Open Payments source 2025-12-10 · JAZZ PHARMACEUTICALS INC. · $16.28 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$272.50	12	2025
Source payment records 2025-02-04 · Teva Pharmaceuticals USA, Inc. · $18.46 · Open Payments source 2025-02-20 · Teva Pharmaceuticals USA, Inc. · $121.55 · Open Payments source 2025-03-10 · Teva Pharmaceuticals USA, Inc. · $18.89 · Open Payments source 2025-04-17 · Teva Pharmaceuticals USA, Inc. · $17.83 · Open Payments source 2025-06-05 · Teva Pharmaceuticals USA, Inc. · $18.65 · Open Payments source 2025-06-27 · Teva Pharmaceuticals USA, Inc. · $16.07 · Open Payments source 2025-07-15 · Teva Pharmaceuticals USA, Inc. · $6.14 · Open Payments source 2025-08-04 · Teva Pharmaceuticals USA, Inc. · $12.14 · Open Payments source 2025-08-26 · Teva Pharmaceuticals USA, Inc. · $5.19 · Open Payments source 2025-09-22 · Teva Pharmaceuticals USA, Inc. · $4.90 · Open Payments source 2025-10-28 · Teva Pharmaceuticals USA, Inc. · $16.15 · Open Payments source 2025-12-08 · Teva Pharmaceuticals USA, Inc. · $16.53 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$185.77	11	2025
Source payment records 2025-01-10 · Alkermes, Inc. · $16.12 · Open Payments source 2025-02-10 · Alkermes, Inc. · $11.35 · Open Payments source 2025-03-19 · Alkermes, Inc. · $20.29 · Open Payments source 2025-04-23 · Alkermes, Inc. · $14.36 · Open Payments source 2025-05-12 · Alkermes, Inc. · $19.06 · Open Payments source 2025-06-25 · Alkermes, Inc. · $18.14 · Open Payments source 2025-07-09 · Alkermes, Inc. · $16.09 · Open Payments source 2025-08-05 · Alkermes, Inc. · $16.95 · Open Payments source 2025-09-29 · Alkermes, Inc. · $16.00 · Open Payments source 2025-10-30 · Alkermes, Inc. · $21.13 · Open Payments source 2025-12-01 · Alkermes, Inc. · $16.28 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$173.12	12	2025
Source payment records 2025-01-23 · Takeda Pharmaceuticals U.S.A., Inc. · $9.08 · Open Payments source 2025-02-18 · Takeda Pharmaceuticals U.S.A., Inc. · $17.59 · Open Payments source 2025-03-03 · Takeda Pharmaceuticals U.S.A., Inc. · $5.39 · Open Payments source 2025-03-24 · Takeda Pharmaceuticals U.S.A., Inc. · $17.58 · Open Payments source 2025-05-27 · Takeda Pharmaceuticals U.S.A., Inc. · $15.59 · Open Payments source 2025-08-11 · Takeda Pharmaceuticals U.S.A., Inc. · $11.11 · Open Payments source 2025-09-10 · Takeda Pharmaceuticals U.S.A., Inc. · $17.08 · Open Payments source 2025-09-24 · Takeda Pharmaceuticals U.S.A., Inc. · $16.06 · Open Payments source 2025-11-05 · Takeda Pharmaceuticals U.S.A., Inc. · $13.58 · Open Payments source 2025-11-24 · Takeda Pharmaceuticals U.S.A., Inc. · $18.29 · Open Payments source 2025-12-03 · Takeda Pharmaceuticals U.S.A., Inc. · $19.02 · Open Payments source 2025-12-18 · Takeda Pharmaceuticals U.S.A., Inc. · $12.75 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$164.64	10	2025
Source payment records 2025-01-10 · Alkermes, Inc. · $16.12 · Open Payments source 2025-02-10 · Alkermes, Inc. · $11.35 · Open Payments source 2025-03-19 · Alkermes, Inc. · $20.29 · Open Payments source 2025-04-23 · Alkermes, Inc. · $14.36 · Open Payments source 2025-05-12 · Alkermes, Inc. · $19.06 · Open Payments source 2025-06-25 · Alkermes, Inc. · $18.14 · Open Payments source 2025-07-09 · Alkermes, Inc. · $16.09 · Open Payments source 2025-08-05 · Alkermes, Inc. · $16.95 · Open Payments source 2025-09-29 · Alkermes, Inc. · $16.00 · Open Payments source 2025-12-01 · Alkermes, Inc. · $16.28 · Open Payments source
WELLBUTRIN Normalized: wellbutrin	Drug	Bausch Health US, LLC	$152.66	11	2025
Source payment records 2025-02-28 · Bausch Health US, LLC · $14.55 · Open Payments source 2025-04-07 · Bausch Health US, LLC · $16.43 · Open Payments source 2025-05-19 · Bausch Health US, LLC · $18.14 · Open Payments source 2025-06-18 · Bausch Health US, LLC · $14.93 · Open Payments source 2025-07-15 · Bausch Health US, LLC · $13.60 · Open Payments source 2025-08-18 · Bausch Health US, LLC · $12.53 · Open Payments source 2025-10-06 · Bausch Health US, LLC · $0.77 · Open Payments source 2025-10-06 · Bausch Health US, LLC · $8.47 · Open Payments source 2025-11-04 · Bausch Health US, LLC · $18.14 · Open Payments source 2025-12-09 · Bausch Health US, LLC · $18.79 · Open Payments source 2025-12-16 · Bausch Health US, LLC · $16.31 · Open Payments source
XYREM Normalized: xyrem	Drug	JAZZ PHARMACEUTICALS INC.	$150.00	1	2025
Source payment records 2025-01-28 · JAZZ PHARMACEUTICALS INC. · $150.00 · Open Payments source
Sunosi Normalized: sunosi	Drug	Axsome Therapeutics, Inc.	$149.96	3	2025
Source payment records 2025-06-03 · Axsome Therapeutics, Inc. · $14.36 · Open Payments source 2025-06-17 · Axsome Therapeutics, Inc. · $118.34 · Open Payments source 2025-12-10 · Axsome Therapeutics, Inc. · $17.26 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$145.30	11	2025
Source payment records 2025-01-21 · ABBVIE INC. · $3.49 · Open Payments source 2025-03-05 · ABBVIE INC. · $16.95 · Open Payments source 2025-03-31 · ABBVIE INC. · $8.45 · Open Payments source 2025-06-09 · ABBVIE INC. · $19.96 · Open Payments source 2025-07-08 · ABBVIE INC. · $15.26 · Open Payments source 2025-08-05 · ABBVIE INC. · $2.82 · Open Payments source 2025-08-19 · ABBVIE INC. · $18.95 · Open Payments source 2025-09-02 · ABBVIE INC. · $3.68 · Open Payments source 2025-09-11 · ABBVIE INC. · $16.71 · Open Payments source 2025-10-06 · ABBVIE INC. · $19.40 · Open Payments source 2025-11-19 · ABBVIE INC. · $19.63 · Open Payments source
REXULTI Normalized: rexulti	Drug	Otsuka America Pharmaceutical, Inc.	$96.21	6	2025
Source payment records 2025-02-05 · Otsuka America Pharmaceutical, Inc. · $14.61 · Open Payments source 2025-04-07 · Otsuka America Pharmaceutical, Inc. · $17.34 · Open Payments source 2025-07-21 · Otsuka America Pharmaceutical, Inc. · $14.40 · Open Payments source 2025-09-02 · Otsuka America Pharmaceutical, Inc. · $15.39 · Open Payments source 2025-09-25 · Otsuka America Pharmaceutical, Inc. · $17.60 · Open Payments source 2025-10-21 · Otsuka America Pharmaceutical, Inc. · $16.87 · Open Payments source
LOREEV XR Normalized: loreev xr	Drug	Almatica Pharma LLC	$78.12	5	2025
Source payment records 2025-05-22 · Almatica Pharma LLC · $15.66 · Open Payments source 2025-07-17 · Almatica Pharma LLC · $14.06 · Open Payments source 2025-09-17 · Almatica Pharma LLC · $16.74 · Open Payments source 2025-10-13 · Almatica Pharma LLC · $15.62 · Open Payments source 2025-10-20 · Almatica Pharma LLC · $16.04 · Open Payments source
APLENZIN Normalized: aplenzin	Drug	Bausch Health US, LLC	$73.24	6	2025
Source payment records 2025-07-09 · Bausch Health US, LLC · $18.14 · Open Payments source 2025-09-02 · Bausch Health US, LLC · $12.00 · Open Payments source 2025-09-02 · Bausch Health US, LLC · $12.43 · Open Payments source 2025-09-17 · Bausch Health US, LLC · $17.28 · Open Payments source 2025-12-09 · Bausch Health US, LLC · $2.09 · Open Payments source 2025-12-21 · Bausch Health US, LLC · $11.30 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$51.02	3	2025
Source payment records 2025-05-14 · Vanda Pharmaceuticals Inc. · $16.71 · Open Payments source 2025-07-23 · Vanda Pharmaceuticals Inc. · $18.67 · Open Payments source 2025-07-28 · Vanda Pharmaceuticals Inc. · $15.64 · Open Payments source
Dyanavel XR Normalized: dyanavel xr	Drug	Tris Pharma Inc	$27.60	2	2025
Source payment records 2025-11-13 · Tris Pharma Inc · $14.07 · Open Payments source 2025-12-18 · Tris Pharma Inc · $13.53 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$19.54	2	2025
Source payment records 2025-03-18 · Axsome Therapeutics, Inc. · $11.98 · Open Payments source 2025-08-13 · Axsome Therapeutics, Inc. · $7.56 · Open Payments source
Jornay PM Normalized: jornay pm	Drug	Collegium Pharmaceutical, Inc.	$15.22	1	2025
Source payment records 2025-05-28 · Collegium Pharmaceutical, Inc. · $15.22 · Open Payments source
WAKIX Normalized: wakix	Drug	HARMONY BIOSCIENCES LLC	$14.11	1	2025
Source payment records 2025-08-28 · HARMONY BIOSCIENCES LLC · $14.11 · Open Payments source
Azstarys Normalized: azstarys	Drug	Corium, LLC	$6.62	1	2025
Source payment records 2025-07-24 · Corium, LLC · $6.62 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
Azstarys azstarys	2025	Azstarys	2024	11 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	63	exact normalized	Medicare Part D
Dyanavel XR dyanavel xr	2025	Dyanavel Xr	2024	11 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
Sunosi sunosi	2025	Sunosi	2024	11 Beneficiary count suppressed	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	58 Beneficiary count suppressed	exact normalized	Medicare Part D
XYWAV xywav	2025	Xywav	2024	22 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VIIBRYD open payments reported associated product	CMS Open Payments — General Payments 57 supporting records · 55 recipient NPIs · example record 1201398050	Viibryd · 2024 Exact normalized brand match · 1 Part D row	48	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	58	suppressed by CMS
Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	Sunosi open payments reported associated product	CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059	Sunosi · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
Corium, LLC Exact reporting entity; no affiliate inference	2025	Azstarys open payments reported associated product	CMS Open Payments — General Payments 54930 supporting records · 15827 recipient NPIs · example record 1185762907	Azstarys · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	63	14
JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference	2025	XYWAV open payments reported associated product	CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700	Xywav · 2024 Exact normalized brand match · 1 Part D row	22	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
Tris Pharma Inc Exact reporting entity; no affiliate inference	2025	Dyanavel XR open payments reported associated product	CMS Open Payments — General Payments 17868 supporting records · 7985 recipient NPIs · example record 1192249449	Dyanavel Xr · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Bupropion Xl	Bupropion Hcl	498	46
Lamotrigine	Lamotrigine	415	45
Trazodone Hcl	Trazodone Hcl	413	62
Alprazolam	Alprazolam	326	59
Escitalopram Oxalate	Escitalopram Oxalate	307	43
Sertraline Hcl	Sertraline Hcl	283	40
Paroxetine Hcl	Paroxetine Hcl	199	28
Duloxetine Hcl	Duloxetine Hcl	197	18
Topiramate	Topiramate	192	36
Memantine Hcl	Memantine Hcl	182	31
Quetiapine Fumarate	Quetiapine Fumarate	164	24
Mirtazapine	Mirtazapine	163	23
Doxepin Hcl	Doxepin Hcl	151	26
Prazosin Hcl	Prazosin Hcl	141	20
Pregabalin	Pregabalin	125	14
Gabapentin	Gabapentin	124	24
Diazepam	Diazepam	119	19
Olanzapine	Olanzapine	118	12
Lorazepam	Lorazepam	113	26
Clonazepam	Clonazepam	112	19
Fluoxetine Hcl	Fluoxetine Hcl	106	16
Divalproex Sodium Er	Divalproex Sodium	104	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	94	18
Bupropion Hcl Sr	Bupropion Hcl	79	suppressed
Lurasidone Hcl	Lurasidone Hcl	77	12
Buspirone Hcl	Buspirone Hcl	72	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	66	15
Caplyta	Lumateperone Tosylate	63	14
Venlafaxine Hcl Er	Venlafaxine Hcl	62	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	58	suppressed
Lithium Carbonate	Lithium Carbonate	58	suppressed
Vraylar	Cariprazine Hcl	58	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	54	suppressed
Vilazodone Hcl	Vilazodone Hcl	53	suppressed
Donepezil Hcl	Donepezil Hcl	51	suppressed
Propranolol Hcl	Propranolol Hcl	51	11
Lamictal	Lamotrigine	48	suppressed
Viibryd	Vilazodone Hcl	48	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	46	suppressed
Propranolol Hcl Er	Propranolol Hcl	45	suppressed
Risperidone	Risperidone	38	suppressed
Aripiprazole	Aripiprazole	37	suppressed
Modafinil	Modafinil	37	suppressed
Benztropine Mesylate	Benztropine Mesylate	34	suppressed
Dexmethylphenidate Hcl Er	Dexmethylphenidate Hcl	32	suppressed
Dexmethylphenidate Hcl	Dexmethylphenidate Hcl	30	suppressed
Clomipramine Hcl	Clomipramine Hcl	27	suppressed
Imipramine Hcl	Imipramine Hcl	27	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	27	suppressed
Emsam	Selegiline	25	suppressed
Clozapine	Clozapine	24	suppressed
Zonisamide	Zonisamide	23	suppressed
Xywav	Sodium,calcium,mag,pot Oxybate	22	suppressed
Asenapine Maleate	Asenapine Maleate	21	suppressed
Guanfacine Hcl	Guanfacine Hcl	21	suppressed
Lithium Carbonate Er	Lithium Carbonate	21	suppressed
Memantine Hcl Er	Memantine Hcl	21	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	20	suppressed
Oxcarbazepine	Oxcarbazepine	20	suppressed
Disulfiram	Disulfiram	17	suppressed
Meclizine Hcl	Meclizine Hcl	16	suppressed
Dextroamphetamine Sulfate	Dextroamphetamine Sulfate	15	suppressed
Fetzima	Levomilnacipran Hcl	15	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	15	suppressed
Nefazodone Hcl	Nefazodone Hcl	14	suppressed
Anafranil	Clomipramine Hcl	13	suppressed
Depakote	Divalproex Sodium	13	suppressed
Eszopiclone	Eszopiclone	13	suppressed
Metoprolol Succinate	Metoprolol Succinate	13	suppressed
Ondansetron Hcl	Ondansetron Hcl	13	suppressed
Thiothixene	Thiothixene	13	suppressed
Amantadine	Amantadine Hcl	12	suppressed
Carbamazepine Er	Carbamazepine	12	suppressed
Neurontin	Gabapentin	12	suppressed
Provigil	Modafinil	12	suppressed
Rexulti	Brexpiprazole	12	suppressed
Thioridazine Hcl	Thioridazine Hcl	12	suppressed
Triazolam	Triazolam	12	suppressed
Wellbutrin Xl	Bupropion Hcl	12	suppressed
Azstarys	Serdexmethylphen/Dexmethylphen	11	suppressed
Cefuroxime	Cefuroxime Axetil	11	suppressed
Cymbalta	Duloxetine Hcl	11	suppressed
Dyanavel Xr	Amphetamine	11	suppressed
Phenelzine Sulfate	Phenelzine Sulfate	11	suppressed
Rivastigmine	Rivastigmine Tartrate	11	suppressed
Selegiline Hcl	Selegiline Hcl	11	suppressed
Sunosi	Solriamfetol Hcl	11	suppressed
Temazepam	Temazepam	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$112,559.09 · 215 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	APLENZIN, ARISTADA, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, Dyanavel XR, FANAPT, Jornay PM, LOREEV XR, LYBALVI, REXULTI, Sunosi, TRINTELLIX, VRAYLAR, WAKIX, WELLBUTRIN, XYREM, XYWAV	8	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Azstarys play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error